@jpmkane.bsky.social
Passionate about neuroscience? 🧠
We’re recruiting a PhD student to join INSPECT-DLB - improving the diagnosis of dementia with Lewy bodies.
Work at QUB with @ecebayram.bsky.social, Dr Claire McEvoy, me & team on this @lewybodysociety.bsky.social-funded project.
🔗 tinyurl.com/yck7466a
We’re recruiting a PhD student to join INSPECT-DLB - improving the diagnosis of dementia with Lewy bodies.
Work at QUB with @ecebayram.bsky.social, Dr Claire McEvoy, me & team on this @lewybodysociety.bsky.social-funded project.
🔗 tinyurl.com/yck7466a
Investigating the specificity and primary predictive value of the clinical diagnostic criteria for dementia with Lewy bodies (DLB) (InSpecT-DLB) at Queen’s University Belfast on FindAPhD.com
PhD Project - Investigating the specificity and primary predictive value of the clinical diagnostic criteria for dementia with Lewy bodies (DLB) (InSpecT-DLB) at Queen’s University Belfast, listed on ...
www.findaphd.com
September 15, 2025 at 4:39 PM
Passionate about neuroscience? 🧠
We’re recruiting a PhD student to join INSPECT-DLB - improving the diagnosis of dementia with Lewy bodies.
Work at QUB with @ecebayram.bsky.social, Dr Claire McEvoy, me & team on this @lewybodysociety.bsky.social-funded project.
🔗 tinyurl.com/yck7466a
We’re recruiting a PhD student to join INSPECT-DLB - improving the diagnosis of dementia with Lewy bodies.
Work at QUB with @ecebayram.bsky.social, Dr Claire McEvoy, me & team on this @lewybodysociety.bsky.social-funded project.
🔗 tinyurl.com/yck7466a
We are counting down for #AAIC25 and to catch up with our #LBDPIA members in person 😍 As we wait patiently, we prepared a webpage for you to find us, check out our work and join our team:
sites.google.com/view/lbdpia-...
sites.google.com/view/lbdpia-...
July 17, 2025 at 9:11 PM
We are counting down for #AAIC25 and to catch up with our #LBDPIA members in person 😍 As we wait patiently, we prepared a webpage for you to find us, check out our work and join our team:
sites.google.com/view/lbdpia-...
sites.google.com/view/lbdpia-...
🎓 Are you an early-career researcher in #LewyBodyDementia? Join us at Lewy Connect, hosted by LBDA at #AAIC2025!
🗓️ July 29, 6–8pm
📍 InterContinental Toronto Centre
🔗 Network, meet LBD leaders, build your career!
RSVP now—space is limited! 👇
doodle.com/sign-up-shee...
🗓️ July 29, 6–8pm
📍 InterContinental Toronto Centre
🔗 Network, meet LBD leaders, build your career!
RSVP now—space is limited! 👇
doodle.com/sign-up-shee...
Doodle
Doodle is the simplest way to schedule meetings with clients, colleagues, or friends. Find the best time for one-to-ones and team meetings with our user-friendly calendar tool. Get started today!
doodle.com
July 14, 2025 at 9:07 PM
🎓 Are you an early-career researcher in #LewyBodyDementia? Join us at Lewy Connect, hosted by LBDA at #AAIC2025!
🗓️ July 29, 6–8pm
📍 InterContinental Toronto Centre
🔗 Network, meet LBD leaders, build your career!
RSVP now—space is limited! 👇
doodle.com/sign-up-shee...
🗓️ July 29, 6–8pm
📍 InterContinental Toronto Centre
🔗 Network, meet LBD leaders, build your career!
RSVP now—space is limited! 👇
doodle.com/sign-up-shee...
There’s a lot of DLB research happening, but what are we actually asking people with DLB and their care partners? Which perspectives are we missing?
@qubelfastofficial.bsky.social PhD candidate Paula Sinéad Donnelly leads this insightful scoping review👇
alzres.biomedcentral.com/articles/10....
@qubelfastofficial.bsky.social PhD candidate Paula Sinéad Donnelly leads this insightful scoping review👇
alzres.biomedcentral.com/articles/10....
Research on the perspectives of people affected by dementia with Lewy bodies: a scoping review - Alzheimer's Research & Therapy
Background Dementia with Lewy bodies (DLB) is associated with specific challenges, including heterogeneity in clinical presentation and a less favourable prognosis relative to other dementia subtypes....
alzres.biomedcentral.com
May 27, 2025 at 10:08 AM
There’s a lot of DLB research happening, but what are we actually asking people with DLB and their care partners? Which perspectives are we missing?
@qubelfastofficial.bsky.social PhD candidate Paula Sinéad Donnelly leads this insightful scoping review👇
alzres.biomedcentral.com/articles/10....
@qubelfastofficial.bsky.social PhD candidate Paula Sinéad Donnelly leads this insightful scoping review👇
alzres.biomedcentral.com/articles/10....
Last week @qubelfastofficial.bsky.social we were delighted to host Dr Yuto Satake from Osaka University and @ucl.ac.uk to discuss his work on AD & DLB biomarkers, very late onset psychosis and tackling loneliness with SoTa the robot. Come back soon Yuto!
May 27, 2025 at 9:30 AM
Last week @qubelfastofficial.bsky.social we were delighted to host Dr Yuto Satake from Osaka University and @ucl.ac.uk to discuss his work on AD & DLB biomarkers, very late onset psychosis and tackling loneliness with SoTa the robot. Come back soon Yuto!
We were joined today by attendees from FORTY-SIX countries!
🇦🇫 🇦🇽 🇩🇿 🇦🇴 🇦🇷 🇦🇿 🇧🇷 🇧🇳 🇧🇫 🇨🇦 🇨🇱 🇨🇳 🇨🇴 🇨🇿 🇪🇬 🇬🇪 🇩🇪 🇬🇭 🇬🇷 🇭🇰 🇮🇳 🇮🇩 🇮🇪 🇰🇪 🇲🇹 🇲🇺 🇲🇲 🇳🇬 🇵🇰 🇵🇪 🇵🇭 🇸🇦 🇸🇬 🇿🇦 🇪🇸 🇱🇰 🇸🇪 🇹🇼 🇹🇭 🇹🇹 🇹🇳 🇹🇷 🇬🇧 🇺🇸 🇻🇪 🇻🇳
🇦🇫 🇦🇽 🇩🇿 🇦🇴 🇦🇷 🇦🇿 🇧🇷 🇧🇳 🇧🇫 🇨🇦 🇨🇱 🇨🇳 🇨🇴 🇨🇿 🇪🇬 🇬🇪 🇩🇪 🇬🇭 🇬🇷 🇭🇰 🇮🇳 🇮🇩 🇮🇪 🇰🇪 🇲🇹 🇲🇺 🇲🇲 🇳🇬 🇵🇰 🇵🇪 🇵🇭 🇸🇦 🇸🇬 🇿🇦 🇪🇸 🇱🇰 🇸🇪 🇹🇼 🇹🇭 🇹🇹 🇹🇳 🇹🇷 🇬🇧 🇺🇸 🇻🇪 🇻🇳
Fantastic to host today's @istaart.bsky.social #LBDPIA Clinical Case Review webinar, with presentations from Dra. Cecilia Fernández & Drs Agnew, Garcia & Barton from @belfasttrust.bsky.social.
Tomorrow's webinar will discuss the same cases in Spanish - register here istaart.alz.org/events/item/...
Tomorrow's webinar will discuss the same cases in Spanish - register here istaart.alz.org/events/item/...
May 12, 2025 at 9:23 PM
We were joined today by attendees from FORTY-SIX countries!
🇦🇫 🇦🇽 🇩🇿 🇦🇴 🇦🇷 🇦🇿 🇧🇷 🇧🇳 🇧🇫 🇨🇦 🇨🇱 🇨🇳 🇨🇴 🇨🇿 🇪🇬 🇬🇪 🇩🇪 🇬🇭 🇬🇷 🇭🇰 🇮🇳 🇮🇩 🇮🇪 🇰🇪 🇲🇹 🇲🇺 🇲🇲 🇳🇬 🇵🇰 🇵🇪 🇵🇭 🇸🇦 🇸🇬 🇿🇦 🇪🇸 🇱🇰 🇸🇪 🇹🇼 🇹🇭 🇹🇹 🇹🇳 🇹🇷 🇬🇧 🇺🇸 🇻🇪 🇻🇳
🇦🇫 🇦🇽 🇩🇿 🇦🇴 🇦🇷 🇦🇿 🇧🇷 🇧🇳 🇧🇫 🇨🇦 🇨🇱 🇨🇳 🇨🇴 🇨🇿 🇪🇬 🇬🇪 🇩🇪 🇬🇭 🇬🇷 🇭🇰 🇮🇳 🇮🇩 🇮🇪 🇰🇪 🇲🇹 🇲🇺 🇲🇲 🇳🇬 🇵🇰 🇵🇪 🇵🇭 🇸🇦 🇸🇬 🇿🇦 🇪🇸 🇱🇰 🇸🇪 🇹🇼 🇹🇭 🇹🇹 🇹🇳 🇹🇷 🇬🇧 🇺🇸 🇻🇪 🇻🇳
Reposted
📢📢 @istaart.bsky.social #DemenciaConCuerposDeLewy Seminario de Casos Clínicos en español tendrá lugar el 13 de mayo,10am US CT📢📢 #LBDPIA vicepresidente
@frodriguezporcel.bsky.social moderará con oradores fabulosos Ceci Fernandez,Ruth Agnew&Fernando Garcia
Regístrate!
alz-org.zoom.us/webinar/regi...
@frodriguezporcel.bsky.social moderará con oradores fabulosos Ceci Fernandez,Ruth Agnew&Fernando Garcia
Regístrate!
alz-org.zoom.us/webinar/regi...
April 8, 2025 at 5:02 PM
📢📢 @istaart.bsky.social #DemenciaConCuerposDeLewy Seminario de Casos Clínicos en español tendrá lugar el 13 de mayo,10am US CT📢📢 #LBDPIA vicepresidente
@frodriguezporcel.bsky.social moderará con oradores fabulosos Ceci Fernandez,Ruth Agnew&Fernando Garcia
Regístrate!
alz-org.zoom.us/webinar/regi...
@frodriguezporcel.bsky.social moderará con oradores fabulosos Ceci Fernandez,Ruth Agnew&Fernando Garcia
Regístrate!
alz-org.zoom.us/webinar/regi...
Fantastic to host today's @istaart.bsky.social #LBDPIA Clinical Case Review webinar, with presentations from Dra. Cecilia Fernández & Drs Agnew, Garcia & Barton from @belfasttrust.bsky.social.
Tomorrow's webinar will discuss the same cases in Spanish - register here istaart.alz.org/events/item/...
Tomorrow's webinar will discuss the same cases in Spanish - register here istaart.alz.org/events/item/...
May 12, 2025 at 4:44 PM
Fantastic to host today's @istaart.bsky.social #LBDPIA Clinical Case Review webinar, with presentations from Dra. Cecilia Fernández & Drs Agnew, Garcia & Barton from @belfasttrust.bsky.social.
Tomorrow's webinar will discuss the same cases in Spanish - register here istaart.alz.org/events/item/...
Tomorrow's webinar will discuss the same cases in Spanish - register here istaart.alz.org/events/item/...
Genial haber sido anfitrión del seminario web de Revisión de Casos Clínicos @istaart.bsky.social #LBDPIA de hoy con Dra. Cecilia Fernández y Drs. Agnew, Garcia y Barton de @belfasttrust.bsky.social.
Regístrate aquí para nuestro seminario web en español mañana: istaart.alz.org/events/item/...
Regístrate aquí para nuestro seminario web en español mañana: istaart.alz.org/events/item/...
May 12, 2025 at 4:44 PM
Genial haber sido anfitrión del seminario web de Revisión de Casos Clínicos @istaart.bsky.social #LBDPIA de hoy con Dra. Cecilia Fernández y Drs. Agnew, Garcia y Barton de @belfasttrust.bsky.social.
Regístrate aquí para nuestro seminario web en español mañana: istaart.alz.org/events/item/...
Regístrate aquí para nuestro seminario web en español mañana: istaart.alz.org/events/item/...
Reposted
Don't let anyone tell you that you can't live your dreams
February 25, 2025 at 7:29 PM
Don't let anyone tell you that you can't live your dreams
Reposted
ISTAART is on Bluesky! Follow us as we discuss the latest in research and treatment and make connections to grow the global dementia science community.
January 23, 2025 at 3:44 PM
ISTAART is on Bluesky! Follow us as we discuss the latest in research and treatment and make connections to grow the global dementia science community.
December 5, 2024 at 11:55 PM
@kaanthanj.bsky.social the profile pic 😂😂😂
November 17, 2024 at 10:23 PM
@kaanthanj.bsky.social the profile pic 😂😂😂
@carlaabdelnour.bsky.social bienvenida Carla!
November 17, 2024 at 8:52 PM
@carlaabdelnour.bsky.social bienvenida Carla!
@rikossenkoppele.bsky.social welcome Rik!
November 17, 2024 at 6:18 PM
@rikossenkoppele.bsky.social welcome Rik!
Reposted
📣 Breaking News
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
November 14, 2024 at 5:18 PM
📣 Breaking News
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
European Medicines Agency has decided to approve lecanemab for early Alzheimer’s with some restrictions.
This follows and mirrors a positive MHRA decision earlier in the year.
These treatments are modest at best but do represent some progress were making in Alzheimer’s research.
EU medicines agency has revised its initial verdict on lecanemab in (non ApoE4 homozygous) Alzheimer’s disease - recommending authorisation to EU bodies
www.ema.europa.eu/en/news/leqe...
www.ema.europa.eu/en/news/leqe...
Leqembi recommended for treatment of early Alzheimer’s disease | European Medicines Agency (EMA)
Re-examination concludes that benefits outweigh risks in a restricted patient population
www.ema.europa.eu
November 14, 2024 at 6:32 PM
EU medicines agency has revised its initial verdict on lecanemab in (non ApoE4 homozygous) Alzheimer’s disease - recommending authorisation to EU bodies
www.ema.europa.eu/en/news/leqe...
www.ema.europa.eu/en/news/leqe...
A summary of EPIC training.
November 13, 2024 at 4:32 PM
A summary of EPIC training.
